Skip to main content
Equibles
SNDX logo

SNDX · Syndax Pharmaceuticals Inc

Track SNDX — free

Use SNDX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SNDX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$19.84 +0.76 (+3.98%) At close · Aug 14
Market Cap
$1.77B
Shares
89.30M

Syndax Pharmaceuticals Inc Earnings Call Transcripts

Every quarterly earnings call for Syndax Pharmaceuticals Inc (SNDX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$44.62M '23 Q2 23-08-03 · $ −$51.15M '23 Q3 23-11-02 · $ −$72.40M '24 Q1 24-05-08 · $3.50M −$68.06M '24 Q2 24-08-01 · $12.50M −$84.13M '24 Q3 24-11-05 · $7.68M −$94.17M '24 Q4 25-03-03 · $20.04M −$84.85M '25 Q1 25-05-05 ▲984.5% $37.96M −$71.85M '25 Q2 25-08-04 ▲267% $45.87M −$60.72M '25 Q3 25-11-03 ▲791.7% $68.48M −$68.01M '25 Q4 26-02-26 ▲223.6% $64.86M −$42.67M '26 Q1 26-04-30 LATEST ▲91.8% $72.79M −$49.36M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Syndax Pharmaceuticals Inc Q2 FY2026 Earnings Call
Positive tone RevuForge (menin inhibitor) commercial performance Upcoming clinical data catalysts Pipeline assets / new clinical programs
Revenue
$72.79M
▲ 91.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Syndax Pharmaceuticals Inc Q1 FY2026 Earnings Call
Revenue
$64.86M
▲ 223.6% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Syndax Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone Revuforj (revumenib) commercial launch and growth NPM1 mutated AML indication expansion Niktimvo (axatilimab) in chronic GVHD
Revenue
$68.48M*
▲ 791.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Syndax Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone Revuforj commercial launch and demand momentum NPM1 label expansion and NCCN guideline inclusion KMT2A penetration and post-transplant maintenance
Revenue
$45.87M
▲ 267% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Syndax Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone Revuforj (revumenib) commercial launch Niktimvo (chronic GVHD) launch Menin inhibitor pipeline / frontline opportunity
Revenue
$37.96M
▲ 984.5% YoY
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Syndax Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone Niktimvo commercial launch Revuforj commercial launch Menin inhibitor first-mover leadership
Revenue
$20.04M
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Syndax Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone Revuforj launch and commercial uptake Combination trials and clinical development pipeline Niktimvo launch in chronic GVHD
Revenue
$7.68M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Syndax Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone Revumenib regulatory progress Clinical data and ASH presentations Frontline combination strategy
Revenue
$12.50M
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Syndax Pharmaceuticals Inc Q2 FY2024 Earnings Call
Confident tone Axatilimab launch in chronic GVHD Revumenib FDA approval and PDUFA delay Combination data presentations at EHA
Revenue
$3.50M
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Syndax Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone revumenib regulatory and clinical progress Commercial launch preparation axatilimab regulatory progress
Revenue
$
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Syndax Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone Revumenib (menin inhibitor) pivotal data and NDA Axatilimab in chronic GVHD approval Combination strategies for revumenib
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Syndax Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Syndax Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Syndax Pharmaceuticals Inc Q1 FY2023 Earnings Call
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Syndax Pharmaceuticals Inc Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Syndax Pharmaceuticals Inc Q3 FY2022 Earnings Call
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Syndax Pharmaceuticals Inc Q2 FY2022 Earnings Call
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Syndax Pharmaceuticals Inc Q1 FY2022 Earnings Call
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Syndax Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$126.58M*
▲ 33209.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Syndax Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$12.38M
▲ 3165.2% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Syndax Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$379,000
▲ 0% YoY
Diluted EPS
$-0.44
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Syndax Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Syndax Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$380,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Syndax Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Syndax Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Syndax Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$379,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Syndax Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$380,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1395937 CUSIP 87164F105 13F (30d) 233 filings 227 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)